Edited by: Hans-Uwe Simon
Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia
Version of Record online: 9 AUG 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 68, Issue 9, pages 1177–1184, September 2013
How to Cite
Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy 2013; 68: 1177–1184., , , , , , .
- Issue online: 18 SEP 2013
- Version of Record online: 9 AUG 2013
- Manuscript Accepted: 10 MAY 2013
- Canada Research Chair Program
- Mayo Foundation
- United States National Institutes of Health. Grant Numbers: (HL058723), (HL065228, RR0109709)
- American Heart Association. Grant Numbers: (05556392), (0855703)
Figure S1. Receiver Operating Characteristic Curve for EPX measurements to identify an ‘eosinophilic airway phenotype’ defined by ≥3% eosinophils in sputum.
Figure S2. EPX-levels in either the serum or plasma of control vs asthma patients failed to display significant differences despite observed differences in both sputum eosinophilia (% of total sputum leukocytes) and sputum EPX levels.
Figure S3. Sputum EPX levels increased as a function of the observed sputum (i.e., airway) eosinophilia.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.